These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9551171)

  • 21. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sparfloxacin and other new fluoroquinolones.
    Richard P; Gutmann L
    J Antimicrob Chemother; 1992 Dec; 30(6):739-44. PubMed ID: 1337749
    [No Abstract]   [Full Text] [Related]  

  • 23. [Lemofloxacin: antimicrobial ability and clinico-pharmacokinetic basis for use in urogenital infections].
    Iakovlev SV
    Urologiia; 2002; (1):11-4. PubMed ID: 11877963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.
    Park HS; Kim HJ; Seol MJ; Choi DR; Choi EC; Kwak JH
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2261-4. PubMed ID: 16723601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H
    Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New fluoroquinolones: characteristics of antimicrobial effect and pharmacokinetics].
    Bondareva NS; Budanov SV
    Antibiot Khimioter; 1998; 43(8):28-33. PubMed ID: 9777103
    [No Abstract]   [Full Text] [Related]  

  • 28. Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1140-2. PubMed ID: 12604557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Moxifloxacin--antimicrobial activity and pharmacokinetic properties].
    Iakovlev VP; Polushkina NR
    Antibiot Khimioter; 2002; 47(5):19-29. PubMed ID: 12365324
    [No Abstract]   [Full Text] [Related]  

  • 30. [Review [new antimicrobial agent series XLI]: lomefloxacin].
    Soejima R; Matsumoto F
    Jpn J Antibiot; 1991 Oct; 44(10):1045-60. PubMed ID: 1662290
    [No Abstract]   [Full Text] [Related]  

  • 31. In vitro activity of sparfloxacin against selected gram-negative blood culture isolates.
    Siristonpun Y; Rojnpisarnvong V; Chongchitmate A; Srimuang S; Tanphaichitra D
    Drugs; 1995; 49 Suppl 2():256. PubMed ID: 8549322
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorocyclopropyl quinolones. 1. Synthesis and structure-activity relationships of 1-(2-fluorocyclopropyl)-3-pyridonecarboxylic acid antibacterial agents.
    Atarashi S; Imamura M; Kimura Y; Yoshida A; Hayakawa I
    J Med Chem; 1993 Oct; 36(22):3444-8. PubMed ID: 8230135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New trifluoromethyl quinolone derivatives: synthesis and investigation of antimicrobial properties.
    Panda SS; Jain SC
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3225-9. PubMed ID: 23611733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.
    Gordon KA; Rhomberg PR; Jones RN
    J Clin Microbiol; 2003 Aug; 41(8):3967-9. PubMed ID: 12904431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lomefloxacin clinical pharmacokinetics.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    Clin Pharmacokinet; 1993 Jul; 25(1):6-19. PubMed ID: 8394795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ESGAB breakpoint determination: temafloxacin.
    Phillips I; Acar J; Baquero F; Bergan T; Forsgren A; Wiedemann B
    Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):991-2. PubMed ID: 1665417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.